Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 188

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 188
---
 fee of $3.5 million.

Required Vote

The approval of the Divestiture Proposal
requires the affirmative vote in person or by proxy of a majority of the outstanding shares of our common stock entitled to vote at the Special Meeting. Aadi stockholders may vote “FOR,” “AGAINST” or “ABSTAIN.” Failures
to vote, abstentions and broker non-votes, if any, will all be counted in the same manner as votes “AGAINST” the Divestiture Proposal.

THE AADI BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” APPROVAL OF THE DIVESTITURE PROPOSAL

- 131 -

PROPOSAL NO. 2:

APPROVAL OF THE PIPE FINANCING PROPOSAL

THE AADI BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT AADI STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE PIPE FINANCING.

Overview

At the Meeting, Aadi stockholders will be asked
to approve, in accordance with applicable rules of the Nasdaq Stock Market, the issuance of shares of Aadi’s common stock in the PIPE Financing. The net proceeds from the PIPE Financing are expected to be used to fund payments due under the
License Agreement and advance Aadi’s development pipeline, business development activities, working capital and other general corporate purposes. Aadi believes the total cash and cash equivalents of Aadi following the closing of the Divestiture
and PIPE Financing will enable the potential attainment of key clinical and development milestones for the ADC Programs.

The PIPE Financing is expected
to close within five business days from receipt of approval of this Proposal No. 2 by Aadi stockholders at the Special Meeting, subject to the satisfaction of certain other closing conditions.

Stockholder Approval Requirement for Purposes of Nasdaq Listing Rule 5635

Nasdaq Listing Rule 5635(a)(1)

Pursuant to Nasdaq Listing
Rule 5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock or other securities convertible into or exercisable for common stock, in connection with the acquisition of the stock or
assets of another company, if such securities are not issued in a public offering and (i) the common stock has, or will have upon issuance, voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such
securities, or (ii) the number of